glp-1 and hypertension Blood Pressure-Lowering Effects of SGLT2 Inhibitors Receptor Agonists | Current Reports Endogenous Activation of Glucagon-Like Peptide-1

The retrospective cohort study by Orandi et al., recently published in The Lancet Diabetes & Endocrinology , offers compelling evidence on the effectiveness and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in kidney transplant recipients with pre-existing type 2 diabetes (1)

Here, the raw powder is converted into various delivery systems

[1] It has also been studied, in NIH-funded research, for HIV-associated fatty liver disease (NAFLD/MASLD), and earlier in its development program it was investigated for indications as varied as wasting, sleep, and mild cognitive impairment most of which did not advance

These changes reduce its binding affinity to IGF-binding proteins (IGFBPs), allowing for a longer half-life (up to 2030 hours) and increased bioavailability in plasma